GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 12, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on June 12, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker for share purchases
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares during the month of June 2025.
Who is acting as GSK's stockbroker for these share purchases?
Merrill Lynch International is acting as GSK's corporate stockbroker for these transactions.
On what date did GSK plc make these announcements?
GSK plc announced these transactions on June 12, 2025.
What type of shares did GSK plc purchase?
GSK plc purchased its own ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased or the total cost?
No, the filing states that GSK plc purchased 'the following number of the Company's ordinary shares' but does not provide the specific quantity or the aggregate dollar amount.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 12, 2025 regarding GSK plc (GLAXF).